Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo / Jan K. BUITELAAR in Journal of Child Psychology and Psychiatry, 50-3 (March 2009)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 50-3 (March 2009) . - p.335-342 Titre : Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo Type de document : Texte imprimé et/ou numérique Auteurs : Jan K. BUITELAAR, Auteur ; Timothy E. WILENS, Auteur ; Shuyu ZHANG, Auteur ; Yu NING, Auteur ; Peter D. FELDMAN, Auteur Année de publication : 2009 Article en page(s) : p.335-342 Langues : Anglais (eng) Mots-clés : Atomoxetine attention-deficit-disorder-with-hyperactivity Life-Participation-Scale quality-of-life Index. décimale : PER Périodiques Résumé : Background: This meta-analysis was designed to determine the relationship between reduction of attention-deficit/hyperactivity disorder (ADHD) symptoms and improvement in functioning by examining short-term changes in functional and symptomatic scores in children and adolescents with ADHD. Methods: Search of atomoxetine's clinical trial database identified four studies involving a symptomatic measure, the ADHD Rating Scale-IV-Parent Version:Investigator-administered and -scored (ADHDRS-IV-Parent:Inv), and a functional measure, the Life Participation Scale for ADHD (LPS). Results: Correlation analysis revealed a moderate-to-strong association between changes in the LPS total versus ADHDRS-IV-Parent:Inv total (r: −.68). The LPS Self-control subscale showed higher correlations than the Happy/Social subscale with the symptomatic measures. Regression analysis also showed high sensitivity for functional measures to changes in symptom severity. Stratified analysis of mean changes in ADHDRS-IV-Parent:Inv scores corresponding to standardized changes in LPS functional scores indicated that a threshold reduction of 16–18 points on the ADHDRS-IV-Parent:Inv total score was needed for functional improvements to become evident. Conclusions: Subjects' symptomatic improvements appear to be reflected in improvements in their social and behavioral function as measured by the LPS. These initial findings warrant verification by replication with other outcome measures. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2008.01960.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=719 [article] Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo [Texte imprimé et/ou numérique] / Jan K. BUITELAAR, Auteur ; Timothy E. WILENS, Auteur ; Shuyu ZHANG, Auteur ; Yu NING, Auteur ; Peter D. FELDMAN, Auteur . - 2009 . - p.335-342. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 50-3 (March 2009) . - p.335-342 Mots-clés : Atomoxetine attention-deficit-disorder-with-hyperactivity Life-Participation-Scale quality-of-life Index. décimale : PER Périodiques Résumé : Background: This meta-analysis was designed to determine the relationship between reduction of attention-deficit/hyperactivity disorder (ADHD) symptoms and improvement in functioning by examining short-term changes in functional and symptomatic scores in children and adolescents with ADHD. Methods: Search of atomoxetine's clinical trial database identified four studies involving a symptomatic measure, the ADHD Rating Scale-IV-Parent Version:Investigator-administered and -scored (ADHDRS-IV-Parent:Inv), and a functional measure, the Life Participation Scale for ADHD (LPS). Results: Correlation analysis revealed a moderate-to-strong association between changes in the LPS total versus ADHDRS-IV-Parent:Inv total (r: −.68). The LPS Self-control subscale showed higher correlations than the Happy/Social subscale with the symptomatic measures. Regression analysis also showed high sensitivity for functional measures to changes in symptom severity. Stratified analysis of mean changes in ADHDRS-IV-Parent:Inv scores corresponding to standardized changes in LPS functional scores indicated that a threshold reduction of 16–18 points on the ADHDRS-IV-Parent:Inv total score was needed for functional improvements to become evident. Conclusions: Subjects' symptomatic improvements appear to be reflected in improvements in their social and behavioral function as measured by the LPS. These initial findings warrant verification by replication with other outcome measures. En ligne : http://dx.doi.org/10.1111/j.1469-7610.2008.01960.x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=719

Disentangling the Overlap between Tourette's Disorder and ADHD / Thomas SPENCER in Journal of Child Psychology and Psychiatry, 39-7 (October 1998)

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 39-7 (October 1998) . - p.1037-1044 Titre : Disentangling the Overlap between Tourette's Disorder and ADHD Type de document : Texte imprimé et/ou numérique Auteurs : Thomas SPENCER, Auteur ; Joseph BIEDERMAN, Auteur ; Margaret HARDING, Auteur ; Deborah O'DONNELL, Auteur ; Timothy E. WILENS, Auteur ; Stephen V. FARAONE, Auteur ; Barbara COFFEY, Auteur ; Daniel GELLER, Auteur Année de publication : 1998 Article en page(s) : p.1037-1044 Langues : Anglais (eng) Mots-clés : Tourette's syndrome  attention deficit disorder  adolescence  school children  comorbidity Index. décimale : PER Périodiques Résumé : Objective: To identify similarities and differences in neuropsychiatric correlates in children with Tourette's syndrome (TS) and those with ADHD. Method: The sample consisted of children with Tourette's syndrome with ADHD(N= 79), children with Tourette's syndrome without ADHD (N= 18), children with ADHD (N= 563), psychiatrically referred children (N= 212), and healthy controls (N= 140). Results: Disorders specifically associated with Tourette's syndrome were obsessive compulsive disorder (OCD) and simple phobias. Rates of other disorders, including other disruptive behavioral, mood, and anxiety disorders, neuropsychologic correlates, and social and school functioning were indistinguishable in children with Tourette's and ADHD. However, children with Tourette's syndrome plus ADHD had more additional comorbid disorders overall and lower psychosocial function than children with ADHD. Conclusions: These findings confirm previously noted associations between Tourette's syndrome and OCD but suggest that disruptive behavioral, mood, and anxiety disorders as well as cognitive dysfunctions may be accounted for by comorbidity with ADHD. However, Tourette's syndrome plus ADHD appears to be a more severe condition than ADHD alone. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=123 [article] Disentangling the Overlap between Tourette's Disorder and ADHD [Texte imprimé et/ou numérique] / Thomas SPENCER, Auteur ; Joseph BIEDERMAN, Auteur ; Margaret HARDING, Auteur ; Deborah O'DONNELL, Auteur ; Timothy E. WILENS, Auteur ; Stephen V. FARAONE, Auteur ; Barbara COFFEY, Auteur ; Daniel GELLER, Auteur . - 1998 . - p.1037-1044. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 39-7 (October 1998) . - p.1037-1044 Mots-clés : Tourette's syndrome  attention deficit disorder  adolescence  school children  comorbidity Index. décimale : PER Périodiques Résumé : Objective: To identify similarities and differences in neuropsychiatric correlates in children with Tourette's syndrome (TS) and those with ADHD. Method: The sample consisted of children with Tourette's syndrome with ADHD(N= 79), children with Tourette's syndrome without ADHD (N= 18), children with ADHD (N= 563), psychiatrically referred children (N= 212), and healthy controls (N= 140). Results: Disorders specifically associated with Tourette's syndrome were obsessive compulsive disorder (OCD) and simple phobias. Rates of other disorders, including other disruptive behavioral, mood, and anxiety disorders, neuropsychologic correlates, and social and school functioning were indistinguishable in children with Tourette's and ADHD. However, children with Tourette's syndrome plus ADHD had more additional comorbid disorders overall and lower psychosocial function than children with ADHD. Conclusions: These findings confirm previously noted associations between Tourette's syndrome and OCD but suggest that disruptive behavioral, mood, and anxiety disorders as well as cognitive dysfunctions may be accounted for by comorbidity with ADHD. However, Tourette's syndrome plus ADHD appears to be a more severe condition than ADHD alone. Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=123

Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse? / Olivia FIGUEROA ; Vita V. MCCABE ; Ty S. SCHEPIS ; John E. SCHULENBERG ; Philip T. VELIZ ; Kennedy S. WERNER ; Timothy E. WILENS in Journal of Child Psychology and Psychiatry, 65-1 (January 2024)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 65-1 (January 2024) . - p.100-111 Titre : Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse? Type de document : Texte imprimé et/ou numérique Auteurs : Olivia FIGUEROA, Auteur ; Vita V. MCCABE, Auteur ; Ty S. SCHEPIS, Auteur ; John E. SCHULENBERG, Auteur ; Philip T. VELIZ, Auteur ; Kennedy S. WERNER, Auteur ; Timothy E. WILENS, Auteur Article en page(s) : p.100-111 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Background To assess whether age of onset and duration of stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) are associated with cocaine, methamphetamine, and prescription stimulant misuse during adolescence. Methods Nationally representative samples of US 10th and 12th grade students (N?=?150,395) from the Monitoring the Future study were surveyed via self-administered questionnaires from 16 annual surveys (2005?2020). Results An estimated 8.2% of youth received stimulant therapy for ADHD during their lifetime (n?=?10,937). More than one in 10 of all youth reported past-year prescription stimulant misuse (10.4%)?past-year cocaine (4.4%) and methamphetamine (2.0%) use were less prevalent. Youth who initiated early stimulant therapy for ADHD (?9?years old) and for long duration (?6?years) did not have significantly increased adjusted odds of cocaine or methamphetamine use relative to population controls (ie, non-ADHD and unmedicated ADHD youth). Youth who initiated late stimulant therapy for ADHD (?10?years old) and for short duration (<1?year) had significantly higher odds of past-year cocaine or prescription stimulant misuse in adolescence than those initiating early stimulant therapy for ADHD (?9?years old) and for long duration (?6?years). Youth who initiated late stimulant therapy for ADHD (?10?years) for short duration (<1?year) had significantly higher odds of past-year cocaine, methamphetamine, and prescription stimulant misuse versus population controls during adolescence. No differences in past-year cocaine, methamphetamine, and prescription stimulant misuse were found between individuals who only used non-stimulant therapy for ADHD relative to youth who initiated early stimulant therapy (?9?years old) and for long duration (?6?years). Conclusions An inverse relationship was found between years of stimulant therapy and illicit and prescription stimulant misuse. Adolescents with later initiation and/or shorter duration of stimulant treatment for ADHD should be monitored for potential illicit and prescription stimulant misuse. En ligne : https://doi.org/10.1111/jcpp.13807 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518 [article] Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse? [Texte imprimé et/ou numérique] / Olivia FIGUEROA, Auteur ; Vita V. MCCABE, Auteur ; Ty S. SCHEPIS, Auteur ; John E. SCHULENBERG, Auteur ; Philip T. VELIZ, Auteur ; Kennedy S. WERNER, Auteur ; Timothy E. WILENS, Auteur . - p.100-111. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 65-1 (January 2024) . - p.100-111 Index. décimale : PER Périodiques Résumé : Background To assess whether age of onset and duration of stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) are associated with cocaine, methamphetamine, and prescription stimulant misuse during adolescence. Methods Nationally representative samples of US 10th and 12th grade students (N?=?150,395) from the Monitoring the Future study were surveyed via self-administered questionnaires from 16 annual surveys (2005?2020). Results An estimated 8.2% of youth received stimulant therapy for ADHD during their lifetime (n?=?10,937). More than one in 10 of all youth reported past-year prescription stimulant misuse (10.4%)?past-year cocaine (4.4%) and methamphetamine (2.0%) use were less prevalent. Youth who initiated early stimulant therapy for ADHD (?9?years old) and for long duration (?6?years) did not have significantly increased adjusted odds of cocaine or methamphetamine use relative to population controls (ie, non-ADHD and unmedicated ADHD youth). Youth who initiated late stimulant therapy for ADHD (?10?years old) and for short duration (<1?year) had significantly higher odds of past-year cocaine or prescription stimulant misuse in adolescence than those initiating early stimulant therapy for ADHD (?9?years old) and for long duration (?6?years). Youth who initiated late stimulant therapy for ADHD (?10?years) for short duration (<1?year) had significantly higher odds of past-year cocaine, methamphetamine, and prescription stimulant misuse versus population controls during adolescence. No differences in past-year cocaine, methamphetamine, and prescription stimulant misuse were found between individuals who only used non-stimulant therapy for ADHD relative to youth who initiated early stimulant therapy (?9?years old) and for long duration (?6?years). Conclusions An inverse relationship was found between years of stimulant therapy and illicit and prescription stimulant misuse. Adolescents with later initiation and/or shorter duration of stimulant treatment for ADHD should be monitored for potential illicit and prescription stimulant misuse. En ligne : https://doi.org/10.1111/jcpp.13807 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=518

Psychiatric comorbidity associated with co-occurring autism spectrum disorder and substance use disorder / Benjamin M. ISENBERG in Research in Autism Spectrum Disorders, 82 (April 2021)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 82 (April 2021) . - 101728 Titre : Psychiatric comorbidity associated with co-occurring autism spectrum disorder and substance use disorder Type de document : Texte imprimé et/ou numérique Auteurs : Benjamin M. ISENBERG, Auteur ; Diana W. WOODWARD, Auteur ; Colin W. BURKE, Auteur ; Lisa A. NOWINSKI, Auteur ; Gagan JOSHI, Auteur ; Timothy E. WILENS, Auteur Article en page(s) : 101728 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  ASD  Substance use disorder  SUD  Conduct disorder Index. décimale : PER Périodiques Résumé : Background Although both autism spectrum disorder (ASD) and substance use disorder (SUD) are both commonly comorbid with other psychiatric conditions, there is a paucity of research on the overlap of these disorders. The primary aim of the present study was to identify the prevalence of psychiatric comorbidities in young adults with SUD and ASD compared to those with ASD only. Method Multivariate logistic regression controlling for age was used to compare the prevalence of psychiatric disorders in a sample of treatment-seeking adult outpatients with a) ASD without SUD and b) ASD with SUD. Psychiatric and SUD diagnoses were determined by semi-structured interview (SCID for DSM IV). Results The sample included 42 patients with ASD only (mean age ± SD = 26.2 ± 8.9 years) and 21 with ASD and SUD (35.2 ± 12.6). High rates of psychopathology were found in both groups. Comorbid conduct disorder (CD) was significantly more prevalent in the ASD + SUD group (25 %) compared to those without SUD (5%; p < 0.05). There were no other significant differences between groups in the rates of non-conduct comorbid psychopathology. Conclusion In both groups, rates of psychopathology were high with CD being significantly more common in young adults with ASD and SUD. These findings highlight the importance of screening for CD in individuals with ASD to mitigate the potential development of comorbid SUD. Further research is needed to determine if CD is a true risk factor for SUD in the ASD population and identify other risk factors. En ligne : https://doi.org/10.1016/j.rasd.2021.101728 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=443 [article] Psychiatric comorbidity associated with co-occurring autism spectrum disorder and substance use disorder [Texte imprimé et/ou numérique] / Benjamin M. ISENBERG, Auteur ; Diana W. WOODWARD, Auteur ; Colin W. BURKE, Auteur ; Lisa A. NOWINSKI, Auteur ; Gagan JOSHI, Auteur ; Timothy E. WILENS, Auteur . - 101728. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 82 (April 2021) . - 101728 Mots-clés : Autism spectrum disorder  ASD  Substance use disorder  SUD  Conduct disorder Index. décimale : PER Périodiques Résumé : Background Although both autism spectrum disorder (ASD) and substance use disorder (SUD) are both commonly comorbid with other psychiatric conditions, there is a paucity of research on the overlap of these disorders. The primary aim of the present study was to identify the prevalence of psychiatric comorbidities in young adults with SUD and ASD compared to those with ASD only. Method Multivariate logistic regression controlling for age was used to compare the prevalence of psychiatric disorders in a sample of treatment-seeking adult outpatients with a) ASD without SUD and b) ASD with SUD. Psychiatric and SUD diagnoses were determined by semi-structured interview (SCID for DSM IV). Results The sample included 42 patients with ASD only (mean age ± SD = 26.2 ± 8.9 years) and 21 with ASD and SUD (35.2 ± 12.6). High rates of psychopathology were found in both groups. Comorbid conduct disorder (CD) was significantly more prevalent in the ASD + SUD group (25 %) compared to those without SUD (5%; p < 0.05). There were no other significant differences between groups in the rates of non-conduct comorbid psychopathology. Conclusion In both groups, rates of psychopathology were high with CD being significantly more common in young adults with ASD and SUD. These findings highlight the importance of screening for CD in individuals with ASD to mitigate the potential development of comorbid SUD. Further research is needed to determine if CD is a true risk factor for SUD in the ASD population and identify other risk factors. En ligne : https://doi.org/10.1016/j.rasd.2021.101728 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=443

---

1 (1 - 4 / 4)